Home / Medical Devices / Antibacterial Drugs Market By Drug Type (Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones, Macrolides, Phenicols, Miscellaneous) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

Antibacterial Drugs Market By Drug Type (Aminoglycosides, B-Lactams, Tetracyclines, Sulfonamides, Quinolones, Macrolides, Phenicols, Miscellaneous) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

Published: Jun 2016 | Report Code: 57891-06-16

This report on global antibacterial drugs market studies various drug classes used for treatment of bacterial infections along with pipeline analysis of upcoming potential drugs.  Bacterial infection, irrespective of its etiology is an important concern in patients with cirrhosis since it is associated with increased morbidity and mortality. According to World Health Organization (WHO), cirrhotic patients from developed countries indicate urinary tract infections (12 – 29%) to be the most frequent cause for bacterial sepsis followed by spontaneous bacterial peritonitis (15 – 23%), respiratory tract infection (6 – 10%) and bacteremia (4-9%).

For the purpose of this study, the various drug classes studied include aminoglycosides, beta-lactams, tetracyclines, sulfonamides, quinolones, macrolides, phenicols and miscellaneous antibacterials. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for antibacterial drugs market comprises projected market sales of Phase III drugs estimated till 2022. The phase III drugs included in the pipeline analysis are solithromycin (Cempra, Inc.), VivaGel/ SPL7013 (Starpharma Holdings Limited), surotomycin (Merck & Co.), MK-3415A (Merck & Co.) and others. The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global antibacterial drugs market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

Antibacterial Drugs Market

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Antibacterial Drugs Market Portaiture
2.2 Global Antibacterial Drugs Treament Market, by Drug Class, 2015 (USD Mn)
2.3 Relativity Analysis: Global Antibacterial Drugs Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Antibacterial Drugs Market: Market Dynamics and Outlook
3.1 Antibacterial Drugs Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Antibacterial Drugs Market, 2015 (Value %)

Chapter 4 GlobalAntibacterial Drugs Market, By Type of Drug Class
4.1 Preface
4.2 Aminoglycosides
4.3 B-Lactams
4.3.1 Penicillins
4.3.2 Carbapenems
4.3.3 Cephalosporins
4.4 Tetracyclines
4.5 Sulfonamides
4.6 Quinolones
4.5 Macrolides
4.6 Phenicols
4.7 Miscellaneous Anti-bacterial Drugs
4.8 Pipeline Analysis
4.8.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.8.1.1 Solithromycin
4.8.1.2 Actoxumab/bezlotoxumab (MK-3415A)
4.8.1.3 Cadazolid
4.8.1.4 Carbavance (meropenem/RPX7009)
4.8.1.5 Eravacycline
4.8.1.6 Omadacycline (PTK-0796)
4.8.1.7 Others
4.8.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Antibacterial Drugs Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Latin America
5.4.1 Brazil
5.4.2 Mexico
5.4.3 Rest of Latin America
5.6 Middle East and Africa

Chapter 6 Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
7.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Merck & Co.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
v.3.4 News Coverage
6.4 Astra Zeneca plc
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 Johnson & Johnson Limited
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Abbott Laboratories
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Eli Lilly and Company
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 Sanofi SA
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 Bristol-Myers Squibb Company
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Bayer AG
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage
6.11 GlaxoSmithKline plc
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage

List Of Table :

TABLE 1 Global Antibacterial Drugs Market, by Type of Drug Class, 2013 – 2022 (USD Mn)
TABLE 2 Global Antibacterial Drugs Market, by Geography, 2013 – 2022 (USD Mn)
TABLE 3 North America Antibacterial Drugs Market, by Country, 2013 – 2022 (USD Mn)
TABLE 4 Europe Antibacterial Drugs Market, by Country, 2013 – 2022 (USD Mn)
TABLE 5 Asia – Pacific Antibacterial Drugs Market, by Country, 2013 – 2022 (USD Mn)
TABLE 6 Latin America Antibacterial Drugs Market, by Country, 2013 – 2022 (USD Mn)

List Of Figure :

FIG. 1 Global Antibacterial Drugs Market, by Type of Drug Class, 2015 (USD Mn)
FIG. 2 Relativity Analysis: Global Antibacterial Drugs Market, by Geography, 2015 & 2022 (USD Mn)
FIG. 3 Attractive Investment Proposition, Global Antibacterial Drugs Market, 2015
FIG. 4 Market Share Analysis: Global Antibacterial Drugs Market, 2015 (Value %)
FIG. 5 Global Aminoglycosides Market, 2013 – 2022 (USD Mn)
FIG. 6 Global Beta-Lactams Market, 20137– 2022 (USD Mn)
FIG. 7 Global Tetracyclines Market, 2013 –2022 (USD Mn)
FIG. 8 Global SulfonamidesMarket, 2013 – 2022 (USD Mn)
FIG. 9 Global Quinolones Market, 2013 – 2022 (USD Mn)
FIG. 10 Global Macrolides Market, 2013 – 2022 (USD Mn)
FIG. 11 Global Phenicols Market, 2013 – 2022 (USD Mn)
FIG. 12 Global Miscellaneous Anti-bacterial Drugs Market, 2013 – 2022 (USD Mn)
FIG. 13 Pipeline Analysis: Global Solithromycin Market, Upto 2022 (USD Mn)
FIG. 14 Pipeline Analysis: Global Actoxumab/bezlotoxumab (MK-3415A) Market, Upto 2022 (USD Mn)
FIG. 15 Pipeline Analysis: Global Cadazolid Market, Upto 2022 (USD Mn)
FIG. 16 Pipeline Analysis: Global Carbavance (meropenem/RPX7009) Market , Upto 2022 (USD Mn)
FIG. 17 Pipeline Analysis: Global Eravacycline Market, Upto 2022 (USD Mn)
FIG. 18 Pipeline Analysis: Global Omadacycline (PTK-0796) Market, Upto 2022 (USD Mn)
FIG. 19 Pipeline Analysis: Global Other Phase III Drugs Market, Upto 2022 (USD Mn)
FIG. 20 Global U.S.Antibacterial Drugs Market, 2013 – 2022 (USD Mn)
FIG. 21 Global Canada Antibacterial Drugs Market, 2013 – 2022 (USD Mn)
FIG. 22 Global U.K Antibacterial Drugs Market, 2013 – 2022 (USD Mn)
FIG. 23 Global Germany Antibacterial Drugs Market, 2013 – 2022 (USD Mn)
FIG. 24 Global Rest of Europe Antibacterial Drugs Market, 2013 – 2022 (USD Mn)
FIG. 25 Global China Antibacterial Drugs Market, 2013 – 2022 (USD Mn)
FIG. 26 Global Japan Antibacterial Drugs Market, 2013 – 2022 (USD Mn)
FIG. 27 Global Rest of Asia Pacific Antibacterial Drugs Market, 2013 – 2022 (USD Mn)
FIG. 28 Global Brazil Antibacterial Drugs Market, 2013 – 2022 (USD Mn)
FIG. 29 Global Mexico Antibacterial Drugs Market, 2013 – 2022 (USD Mn)
FIG. 30 Global Rest of the Latin America Antibacterial Drugs Market, 2013 – 2022 (USD Mn)
FIG. 31 Global Middle East and Africa Antibacterial Drugs Market, 2013 – 2022 (USD Mn)

According to market stakeholders, bacterial infections cause an enormous financial and physical burden of disease throughout the globe and kill millions of humans and animals. A few most common bacterial infections are pneumonia, diarrhea and meningitis, genito-urinary infections and blood infections.  Recently hospital acquired diseases such as tuberculosis, pneumonia, and others are on the rise in many parts of the world. Resistance to antibiotics is now widespread among bacteria and is increasing at an alarming rate.

Based on the type of drug class, the antibacterial drugs market is segmented into:

  • Aminoglycosides
  • Beta-Lactams
  • Tetracyclines
  • Sulfonamides
  • Quinolones
  • Macrolides
  • Phenicols
  • Miscellaneous

Antibacterial Drugs Market

In base year 2015, beta-lactams accounted for the largest market share of 55.8% of the global antibacterial drugs market followed by the quinolones. In the near future these drug classes are expected to experience a decline in their market share during the forecast period 2016 to 2022 because leading brands will lose their market exclusivity, coupled with high rate of clinical trial failures, rising number of drug resistant bacterial strains and high influx of generic drugs. Thus, on the basis of the factors mentioned above, the global antibacterial drugs market is expected to witness slow growth during the forecast period 2016 to 2022. Although, the miscellaneous antibacterial drug class is expected to project noticeable growth along with rising demand for novel therapies against bacterial infections and aging population.

For the purpose of this study, the global antibacterial drugs market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East Africa

Antibacterial Drugs Market

In base year 2015, it was observed that Asia Pacific dominated the overall market and is also projected to witness the fastest growth during the forecast period 2016 - 2022. The key factors assisting the growth of  Asia Pacific antibacterial drugs market are it accounts for the largest infected population in the world with a variety of bacterial infections such as pneumonia, tuberculosis and tetanus, presence of large number of manufacturers of active pharmaceutical ingredient and generic drugs, high disposable income, rising geriatric population, and emerging healthcare infrastructure. North America, followed by Europe, is the second largest antibacterial drugs market globally in terms of revenue. North America and Europe are anticipated to witness slow growth over the forecast period due to stringent regulatory policies, abridged product lifecycle, and generic penetration.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients